Beta Bionics (BBNX) Cash & Equivalents (2023 - 2026)

Beta Bionics has disclosed Cash & Equivalents across 4 years of filings, most recently posting $30.2 million for Q1 2026.

• Cash & Equivalents for Q1 2026 came in at $30.2 million, down 28.85% year-over-year; the trailing twelve-month figure through Mar 2026 was $30.2 million (down 28.85% YoY), and the FY2025 annual result was $31.6 million, up 3.76% from the prior year.
• Cash & Equivalents came in at $30.2 million for Q1 2026 at Beta Bionics, down from $31.6 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $42.5 million in Q1 2025 to a low of $13.0 million in Q2 2024.
• The 4-year median for Cash & Equivalents is $30.3 million (2024), against an average of $28.7 million.
• Across the five-year window, Cash & Equivalents surged 169.21% in 2025 and fell 28.85% in 2026, its largest moves.
• Beta Bionics' Cash & Equivalents stood at $26.6 million in 2023, then advanced by 14.55% to $30.4 million in 2024, then gained by 3.76% to $31.6 million in 2025, then dropped by 4.34% to $30.2 million in 2026.
• The last three Cash & Equivalents figures came in at $30.2 million (Q1 2026), $31.6 million (Q4 2025), and $38.5 million (Q3 2025), per Business Quant data.